Skip to main content

Advertisement

Log in

The mystery of angiographically silent macular oedema due to taxanes

  • Case Report
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Taxanes are widely used anticancer agents, produced from the plants of the genus Taxus (yews). One of the rare side-effects caused by taxanes is a bilateral cystoid macular oedema (CMO). The particularity of this type of CMO is that it is angiographically silent showing no leakage or pooling on fluorescein angiography (FA). To date, the mechanism of this oedema has not been clearly understood and existing theories do not explain this phenomenon very well. Our aim was to report a case of paclitaxel-induced CMO and put forward a putative explanation for this occurrence. A 64-year-old woman presented with a 7-month history of progressively decreasing bilateral visual acuity with an apparently normal fundus. At entry her best-corrected visual acuity (BCVA) was 0.4 for far and near OD and 0.5 for far and near OS. Optical coherence tomography (OCT) revealed a CMO with a central thickness of 561 μm OD and 488 μm OS; there were no signs of intraocular inflammation. FA showed no capillary leakage and quasi absent late hyperfluorescence OU. Indocyanine green angiography was within normal limits. Classical CMO treatment was ineffective and only discontinuation of paclitaxel resulted in recovery of a normal macular structure after 4 weeks with an increase of BCVA to 0.9 OD and 1.0 OS. In order to understand the properties of taxane drug-induced cystoid macular oedema (TDICMO) we compared the spectral OCT findings of our case to an inflammation-induced CMO of equal thickness and to a case of multifocal choroiditis. The plane of separation of TDICMO was above the external limiting membrane in both cases. In contrast to inflammation-induced CMO where the four external bands were well identified, there was attenuation of these bands in TDICMO but no disruption of the layers as seen in multifocal choroiditis, indicating that the fluid in TDICMO had a high viscosity producing a shadow underneath. TDICMO most probably originates from retinal pigment epithelium dysfunction by their effect on microtubule functions and not from vascular leakage. The content of the CMO seems to be made up of viscous fluid. As the origin of the CMO is not inflammatory, classical CMO treatments have no effect and only discontinuation of the taxane drug allows reversal of the CMO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Crown J, Leary MO, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9:24–32

    Article  PubMed  CAS  Google Scholar 

  2. Eisner A, Luoh SW (2011) Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 36:867–885

    PubMed  CAS  Google Scholar 

  3. Teitelbaum BA, Tresley DJ (2003) Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80:277–279

    Article  PubMed  Google Scholar 

  4. Behar A, Lauraine EP, Maurel A, Brun MD, Lagrue G, Chauvin FF, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43:653–658

    Article  PubMed  CAS  Google Scholar 

  5. Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426–3432

    PubMed  CAS  Google Scholar 

  6. Smith SV, Matthew BA, Benz S, Brown DM (2008) Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 126:1605–1606

    Article  PubMed  Google Scholar 

  7. Joshi MM, Garretson BR (2007) Paclitaxel maculopathy. Arch Ophthalmol 125:709–710

    Article  PubMed  Google Scholar 

  8. Bringmann A, Reichenbach A, Wiedemann P (2004) Pathomechanisms of cystoid macular edema. Ophthalmic Res 36:241–249

    Article  PubMed  Google Scholar 

  9. Marmor MF (1999) Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 97:239–249

    Article  PubMed  CAS  Google Scholar 

  10. Telander DG, Sarraf D (2007) Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22:151–153

    Article  PubMed  Google Scholar 

  11. Karakashian S, Bayliff CD (2001) Niacin-induced cystoid macular edema. CJHP 54:35–36

    Google Scholar 

  12. Dajani HM, Lauer AK (2006) Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 41:197–200

    Article  PubMed  Google Scholar 

  13. Michaud LB, Valero V, Hortobagyi G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23:401–428

    Article  PubMed  CAS  Google Scholar 

  14. Mitchison TJ (1992) Compare and contrast actin filaments and microtubules. Mol Biol Cell 3:1309–1315

    PubMed  CAS  Google Scholar 

  15. Burnside B, Bost-Usinger L (1998) The retinal pigment epithelium cytoskeleton. In: Marmor MF, Wolfensberger TJ (eds) The retinal pigment epithelium. Oxford University Press, New York, pp 41–67

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tatiana I. Kuznetcova.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuznetcova, T.I., Cech, P. & Herbort, C.P. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 32, 299–304 (2012). https://doi.org/10.1007/s10792-012-9558-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-012-9558-9

Keywords

Navigation